EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Antonio Passaro, Maise Al Bakir, Emily G Hamilton, Maximilian Diehn, Fabrice André, Sinchita Roy-Chowdhuri, Giannis Mountzios, Ignacio I Wistuba, Charles Swanton, Solange Peters

Cell · 2024-03 · 187 (7) · 1617-1635

DOI: 10.1016/j.cell.2024.02.041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell, 2024-03. Verfasst von Antonio Passaro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms, Precision Medicine. Die Arbeit wurde bisher 705-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplasmsPrecision MedicineHumansMedical OncologyTumor Microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Gustave-Roussy Cancer Center, Paris Saclay University, Villejuif, France.
  • Department of Anatomic Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.

Förderung

  • Medical Research Council
  • NCI NIH HHS

Zitieren

APA

Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell, 187(7), 1617-1635. https://doi.org/10.1016/j.cell.2024.02.041

Vancouver

Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617-1635. doi:10.1016/j.cell.2024.02.041

BibTeX
@article{Passaro2024,
  author = {Passaro, Antonio and Al Bakir, Maise and Hamilton, Emily G and Diehn, Maximilian and André, Fabrice and Roy-Chowdhuri, Sinchita and Mountzios, Giannis and Wistuba, Ignacio I and Swanton, Charles and Peters, Solange},
  title = {Cancer biomarkers: Emerging trends and clinical implications for personalized treatment},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {7},
  pages = {1617--1635},
  doi = {10.1016/j.cell.2024.02.041}
}
Kostenlos starten →